News:

New to the boards? Start with "Welcome! What you need to know as a member of this community"

Main Menu

CD40 as a therapeutic target in Sjogrens syndrome

Started by markt, July 10, 2018, 11:36:53 AM

Previous topic - Next topic

markt

Newer article describing the evidence based rational for use of an investigational monoclonal antibody (mab) for blockade of CD40 and associated immune pathway.

https://www.tandfonline.com/doi/full/10.1080/1744666X.2018.1485492

FYI, Phase-IIb concludes later next month;  I imagine recruitment for larger Phase-III starts shortly thereafter for those that qualify.

https://clinicaltrials.gov/ct2/show/NCT02291029


Polly

This sounds very promising, research for new RA treatments has stopped as far as what my rheumatologist tells me. I've had just about all the RA biologicals, to no avail.

You may have missed this, last month Alex posted this YouTube link. It's about a biologic drug to block CD86:
https://www.youtube.com/watch?v=xe2azAhYOOA
What is most interesting is how they're finding what to block, it's explained well in the video.

Thanks for letting us know about the progress on the CD40 approach. The clinical trials are not available to me but maybe someday there will be a treatment that my doctor will agree to give me! I can hope.

markt


markt

Quote from: Polly on July 10, 2018, 12:56:39 PMThe clinical trials are not available to me but maybe someday there will be a treatment that my doctor will agree to give me! I can hope.

You can apply/petition for treatment outside of the trial.

Google FDA Expanded Access.